TOLL FREE: 888.88.INFECT
PHONE: 517.536.8210
FAX: 517.536.8205

THE WELLHOFF CENTER
7190 S. BROOKLYN RD.
JACKSON, MI 49201

TransPharm Preclinical Solutions TransPharm Preclinical Solutions TransPharm Preclinical Solutions TransPharm Preclinical Solutions

Newsletters

Fall 2017 Newsletter

Posted by on 9:39 am in Newsletters | 0 comments

A Note from the President

The year is coming to a close and 2018 is right around the corner. It’s hard to believe, but January will mark TransPharm’s 10-year anniversary. Our company started with just three employees, but ten years later we have quadrupled in size. The total revenue our first year was $147k; now we do over $2 million annually. Time flies when you’re having fun! To celebrate our landmark anniversary and as a thank you to our clients, we are offering 10% off all studies booked by December 21st. See below for more details.

Also, we’d like to remind you that TransPharm will be closed starting Monday, December 25th and will reopen on Tuesday, January 2nd. The last day for animal deliveries is December 18th, with studies ending on the 22nd. Studies for early January (and any that you wish to be 10% off!) should be booked by December 21st. We will be checking email periodically, and this is the best way to reach us during our break. We wish you and yours a joyous holiday season and a happy new year.

Daniel Ross
President & CEO


10% Off ALL Studies!

Celebrate our 10-year anniversary with 10% off! All studies booked* by 12/21/2017 are eligible for the discount. Contact Marci for a quote today!

*Signed quotes and a purchase order must be received by end of business on Thursday, December 21, 2017.


In the Lab

TransPharm has added a new animal model of induced chronic osteomyelitis (bone infection). Osteomyelitis results in pain, loss of mobility, and significant morbidity. Current treatment requires prolonged antibiotic therapy and surgical debridement of sequestra (dead bone). Due to poor drug penetration into the bone and an increase in antibiotic-resistant bacteria, there is an urgent need for novel therapeutics. Our model serves as a screening tool to identify which antimicrobials are most clinically efficacious.

Animals are challenged via injection into the cancellous bone marrow through the anterior surface of the proximal tibia (see photo). The infection is allowed to incubate for up to 4 weeks before the tibia is harvested for CFU enumeration. The induced chronic osteomyelitis model is currently available for S. aureus and S. epidermidis infections in Sprague-Dawley rats. Additional validations are available upon request.

Santiago R. Lopez, Ph.D.
Chief Scientific Officer


Our Research Process

Interested in learning more about what we do here at TransPharm? This infographic walks you through each step of our research process. As in vivo experts of infectious disease, we are happy to provide a professional consultation to help identify your needs. Our flexible study design means all studies can be customized – you choose your animal strain, pathogen, infection route, treatment, endpoints, and more. Additional validations are available upon request. Contact us today for more information!


Community Involvement

The Brooklyn-Irish Hills Chamber of Commerce hosted their annual Career and College Expo in mid-October. Chief Scientific Officer, Dr. Santiago Lopez, and Associate Scientist, Jeremy Covell, manned the TransPharm booth and had the opportunity to speak with local high school students about scholarship opportunities and our summer internship program. Further, our President and CEO, Dan Ross, was invited to speak to over 800 students, faculty, and staff on the meaning of success in business. We are lucky to have so many events which allow us to stay actively involved in our community.


A Field Trip to TransPharm

Students from Madison High School in Adrian, MI visited TransPharm in early November to gain hands-on laboratory experience. Following a tour of our facility, Dr. Santiago Lopez and teacher Katie McGormley instructed a laboratory activity titled, “Transduction of an antibiotic-resistance gene in E. coli cells.” This experiment introduced the concepts of bacteriophages, horizontal gene transfer, and mutations. The students enjoyed their time in the lab and were excited to see antibiotic-resistant colony growth on their agar plates the following day.

 

 

 

 

 

 

 

 


The Big 400 Tour

Our team had a great time on The Big 400 Tour in October. The Big 400 promotes the economic development, use, and preservation of a 20 mile by 20 mile area in southern central Michigan. We enjoyed visiting local attractions and businesses including a state park, a sustainable farm, an ice cream shop, and the oldest continuously operating cider mill in Michigan. Below is our group photo in front of Mill Creek, the largest tributary of the Huron River.


 

Summer 2017 Newsletter

Posted by on 12:28 pm in Newsletters | 0 comments

A Note from the President

It’s been a busy summer here at TransPharm and we are on track for another record year. Our team has been hard at work and we’re excited to share an inside look at what we do. The video below gives a great overview of our role in preclinical infectious disease research. It highlights our niche focus – animal models of bacteria, viruses, parasites, and fungi – which has cultivated an expertise that sets us apart from other contract research organizations. As specialists, we can serve as professional consultants to help you design a study that meets both your needs and your budget. You’ll also get a glimpse of our state-of-the-art laboratory and animal care facilities, as well as hear about how we manage such quick turn-around times for our clients. We have a passion for knowledge and scientific discovery and feel honored to play even a small part in the drug development process. It is our goal that our work will contribute to new and potentially life-saving therapies. We hope you enjoy the video and don’t forget to subscribe to our YouTube channel to see future content.

Daniel Ross
President & CEO


In the Lab

We are searching for TransPharm’s Next Top Model! Our team has been focused on validating new murine models of infectious disease, including Haemophilus influenzae pneumonia, Staphylococcus epidermidis peritonitis, Streptococcus pyogenes soft tissue infection, and Acinetobacter baumannii deep wound infection. Upcoming validations will follow-up on the 2017 summer internship program projects as well as validating new comparators against H. influenzae, P. acnes, and VRE. Contact us today to request a validation or no-obligation quote.

Speaking of our internship program, it was featured in a recent edition of the Brooklyn Exponent. All four of our 2017 interns – Paige, Brandon, Jen, and Trevor – did a fantastic job in the lab. We are looking forward to meeting next year’s applicants!

Santiago R. Lopez, Ph.D.
Chief Scientific Officer


Publications

Many of our clients have published their research and acknowledged TransPharm’s role in their work. Check out a few of the manuscripts and poster presentations based on studies we’ve completed, including a P. acnes skin infection, a pulmonary model of Pseudomonas aeruginosa, a C. difficile gastrointestinal infection, as well as models of candidiasis, aspergillosis, and cecal ligation and puncture sepsis.


2017 Scholarship Recipients

Each year, TransPharm offers $1,000 scholarships to graduating seniors from local high schools in the Irish Hills. The 2017 scholarships were awarded to three deserving young women pursuing careers in STEM. Congratulations to Hailey Dickens, Mackenzi Collins, and Riley Bollheimer!


 

Spring 2017 Newsletter

Posted by on 8:45 am in Newsletters | 0 comments

A Note from the President

Spring has finally sprung in Michigan and things are looking especially sunny here at TransPharm. We celebrated our best first quarter in history, and the first intern of our summer internship program is finishing up validation of an A. baumanii pulmonary infection model. Lunches are spent at the picnic table on our patio, and everyone is enjoying a newly constructed trail which weaves through the woods to a pond on the property.

Warmer weather isn’t the only change we’ve noticed. Today’s economy relies on technology more than ever before, and a growing number of customers want to interact with businesses in a way that is most convenient for them. For this reason, our team has decided to pursue a different marketing strategy than in years past. In lieu of attending the American Society for Microbiology conference in June, we will be using our resources to expand our digital presence. Keep your eyes open for original media content highlighting our niche services, and be sure follow us on Facebook for the latest and greatest.

Daniel Ross
President & CEO

The trail on our property leads through the woods to a pond nestled among the willow trees.

Wild geraniums (above) and lily of the valley grow along the trail.


In the Lab

Many bacteria live in our gut and on our skin, usually without causing problems. However, serious infections can occur when these bacteria become resistant to antibiotics. Vancomycin-resistant enterococci, or VRE, are one such threat. Although healthy people are unlikely to become infected with VRE, those who are hospitalized or have weakened immune systems are especially at risk.

TransPharm has a well-established murine model of VRE colonization in the gastrointestinal tract, one of the most common sites for infection. Antibiotic pre-treatment provides consistent results, with fecal shedding peaking on Days 3-5 and observed through Day 15. Our screening studies are flexible enough to accommodate studies with prophylactic and/or daily dosing. We also have personnel and areas of our facility dedicated specifically to VRE work. Contact us today for a quote!

Santiago R. Lopez, Ph.D.
Chief Scientific Officer


Marci Peek promoted to Senior Protocol Specialist

We are excited to announce that Marci Peek has been promoted to Senior Protocol Specialist. Marci came to TransPharm in 2010 after 11 years as a study coordinator at the Pfizer Phase I Unit. Her expertise in study scheduling and protocol editing keeps our work running smoothly, and her positive attitude puts a smile on everyone’s face. Marci is an invaluable member of our team and we are proud to have her as an employee and coworker. Please join us in congratulating Marci on her new position.


TransPharm Team Building

Our staff works together to solve problems here at TransPharm, but it turns out we are just as great of a team outside the lab! In March, we used our detective skills to investigate a crime scene at Epiq Escapes. By finding clues and solving puzzles, we broke out of the locked room in near record time. In April, TransPharm became Jackson Certified! Jackson Certified is a community trivia program which challenges businesses and organizations to learn more about Jackson County with the ultimate goal of enhancing community pride. The competition was fierce, but Team “Winner Winner Chicken Dinner” held true to their name and came out on top.

We managed to escape the CSI room in near record time.

The winning team celebrated their victory in Jackson Certified swag.


 

Winter 2017

Posted by on 2:49 pm in Newsletters | 0 comments


A Note from the President

January 2017 marked our 9 year anniversary and the close of another great year here at TransPharm. With 17 new clients in 2016, the TransPharm family now spans over 6 continents. As a result of our continued growth, we were able to reach a major milestone in November: a total of $10M in revenue since I founded the company in 2008. Increased demand also allowed us to welcome some new faces to our team – Brianne Fiero (Associate Scientist) in April, and Brittany Dixon (Scientific Writer) and Emily Gilles (Laboratory Technician) in October.

2016 was also a year of physical growth. A 2,100 sq. ft. addition to our facility, including an expanded animal vivarium and a procedure room, was completed in May. This new space contains both a negative pressure room and a positive pressure room, with corresponding bioBUBBLE® enclosures in each, meaning separate, dedicated areas for C. difficile and germ-free work, respectively. The renovations have already proven advantageous to our clients who currently work in the C. difficile therapy development field. Please contact us for more information.

Finally, I’d like to extend an open invitation to visit us here at TransPharm. We wouldn’t be celebrating these successes without our clients, and we’d love the opportunity to meet you personally and provide a tour of our facilities. Thank you for your business and we look forward to working with you in the new year.

Daniel Ross
President & CEO


Positive pressure bioBUBBLE® enclosures in a separate, pressurized room allow for germ-free studies in vivo.

Negative pressure bioBUBBLE® enclosures in a separate, pressurized room allow for C. difficile studies in vivo.

 

 

 

 

 

 

 


In the Lab

This past summer, six local high school and college students interested in a career in life science participated in TransPharm’s internship program. Each student spent two weeks working on their own model validation project focused on one of the ESKAPE pathogens. These bacteria, listed below, cause the majority of US hospital infections and are increasingly resistant to current antimicrobials.

Intern Joe C. checks his plates for P. aeruginosa.

 

Enterococcus faecium

Staphylococcus aureus

Klebsiella pnuemonia

Acinetobacter baumannii

Pseudomonas aeruginosa

Enterobacter species

 

Thanks to the hard work of these motivated students and historical data, TransPharm now has a validated model for all ESKAPE pathogens, with some pathogens having several models available. Contact us today for quotes or more information.

Due to the popularity and success of last year’s program, I am happy to announce that we will be accepting new interns for a Summer 2017 rotation. This year’s projects will likely follow-up on the work of previous students, moving into soft tissue models and/or pulmonary models and generating PD50 values for various comparator drugs.

Santiago R. Lopez, Ph.D.
Chief Scientific Officer


Ernst and Young
Entrepreneur Of The Year ® Finalist

 

TransPharm staff and guests pose for a photo at the 2016 Entrepreneur Of The Year® gala in Detroit.

Ernst and Young’s Entrepreneur Of The Year ® program celebrates those who are building and leading successful, growing, and dynamic businesses. The award recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance, and personal commitment to their businesses and communities.

Our President and CEO, Daniel Ross, was named as a Finalist for the 2016 Michigan and Northwest Ohio Award. TransPharm staff attended a gala and awards ceremony at the Detroit Institute of Arts on June 23rd.


TransPharm Welcomes New Team Members

Three new faces joined the TransPharm team in 2016. Full bios for all team members can be found on our website.

Brianne Fiero

Brianne received her Bachelor’s degree in Biological Sciences in 2015 from Spring Arbor University. As an Associate Scientist and our Vivarium Manager, Brianne monitors study progress and ensures the vivarium meets AAALAC standards.

 

Brittany Dixon

Brittany earned a Master’s degree in Molecular and Cellular Pathology from the University of Michigan in 2015. As our scientific writer, Brittany graphs and analyzes experimental data, compiles study reports, and writes our quarterly newsletter.

 

Emily Gilles

Emily will graduate with a Bachelor’s degree in Biochemistry from Saginaw Valley State University in 2018. She joined our team as a laboratory technician after an internship last summer. Emily assists with in vitro microbiology and helps maintain our facilities.

 


 

Fall 2014

Posted by on 12:41 pm in Newsletters | 0 comments

A Note from the President

Another year has gone by quickly and 2015 is right around the corner. This January marks our seven-year anniversary. It is hard to believe that eight years has passed since Pfizer R & D closed its doors in Ann Arbor, Michigan. January 22nd, 2007 was the announcement day that made all of us wonder what would happen after Pfizer. I was one of the lucky ones that had a plan shortly after the announcement and that plan was founding TransPharm Preclinical Solutions. We incorporated on April 13th, 2007, started renovation to the lab in September of that year, and opened our doors on January 2nd, 2008.

Today we are considered a global leader for Infectious Disease research and have generated more than 6 million in revenue with over 60 clients around the world. TransPharm has never been stronger and we are eager to see what the future holds for us. During the holidays, we are very thankful to do what we love and even more thankful to you for allowing us to do this important work.

Daniel Ross
President and CEO


Slight Increase in Pricing

Starting in January, TransPharm will be increasing the cost of our studies due to increases in costs from some of our suppliers. We expect the increase to be 5% across the board for all studies, but this could vary depending on study design. Studies booked for January that are scheduled in December will remain at the current price structure.


Holiday Schedule

TransPharm will be closed from around noon on December 24th until January 5th. All studies must end no later than the 24th with preliminary data following mid-day. All mouse orders scheduled for January 5th must be placed before December 24th. No animals will be housed on-site during this closure. Now is the time to get your studies scheduled for the new year.


 

Summer 2014

Posted by on 12:41 pm in Newsletters | 0 comments

A Note from the President

I would like to wish a happy summer to all of you. As we move into warmer weather, vacations and outdoor activities fill our days and time to get things done seems to shorten. Towards that end, I will be brief with this newsletter and announce that TransPharm has finally been awarded PHS registry with the Office of Laboratory Animal Welfare.

Briefly, this means that companies receiving grants from NIH are now allowed to spend those funds directly with TransPharm Preclinical Solutions. This is a huge milestone for us and I know it will open the doors to many smaller companies receiving grant funds. Please see the notice below and use our Assurance # A4707-01 for all future grant applications to the National Institute of Health.

Daniel Ross
President and CEO


21


As always, please feel free to contact us:
Through our website, www.transpharmsite.com
Our toll free INFECT line, 1-888-88-INFECT
Or dial me direct, 1-517-536-8210
Check us out on Facebook


 

Spring 2014

Posted by on 12:41 pm in Newsletters | 0 comments

A Note from the President

At last, I’ve found a few moments to reconnect with our distribution list which is growing every month. TransPharm finished very strong in 2013, with our second best year on record. We’ve also picked up some new clients in the last few months and would like to welcome them to the TransPharm family. I’m also proud to say that we have continued to work with a few clients that have been with us since we opened.

As the saying goes, “Working with us is CONTAGIOUS“…….

Quickly, I would like to address a question a few of you have had about another large project in the works and how it relates to TransPharm and my goals going forward.

I was lucky enough to have the opportunity to purchase a piece of history here in the Irish Hills area where I live. The facility is an original Henry Ford Village Industries site built in the late 1930s. The plot of land it sits on was the first parcel of land deeded in Brooklyn back in 1832.

The plan for this facility is to turn it into an Irish themed destination called the Old Irish Mill. It will include a restaurant, pub, café, park, and Michigan’s largest indoor farmer market. We are very excited about this venture and know it will become one of the favorite tourist stops in the area.

So what will happen to TransPharm? Am I leaving? Who is going to run the show?

Rest assured, nothing will be changing around here anytime soon. My role in this new venture is simply the “idea and finance guy.” I’m currently involved with a lot of the interior demolition and spearheading the general contracting, but that is to get things going in the right direction. I don’t plan to have an active role in the new organizational chart once the facility is up and running. I will likely pass along the progress of this project as it moves forward.

Daniel Ross
President and CEO


TransPharm named Business of the Year

Annette Dupuie, left, presented Dan and Samantha Ross with a plaque naming their company, TransPharm Preclinical Solutions, as the Brooklyn-Irish Hills Chamber of Commerce Business of the Year for 2014.

Annette Dupuie, left, presented Dan and Samantha Ross with a plaque naming their company, TransPharm Preclinical Solutions, as the Brooklyn-Irish Hills Chamber of Commerce Business of the Year for 2014.

Dan Ross, owner of TransPharm Preclinical Solutions in Napoleon, was surprised when he learned his company was being named Business of the Year by the Brooklyn-Irish Hills Chamber of Commerce.

“It is not often that I am speechless,” said Ross. “I really had no idea.”

This year’s Business of the Year opened its doors in January of 2008; they joined the chamber right away. Recently stating that being part of our chamber is like one big family, these owners are adamant about supporting chamber members businesses’ and organizations. They have received many awards and certificates nationally, ranking in the top 2% of all globally accredited facilities. They have even made it on National news, ABC World News with Diane Sawyer. In 2011, this business was named one of the “Michigan 50 Companies to Watch” I have even heard them say they have an open door policy, meaning that ANYONE can schedule a tour to walk through their facility.

Their level of commitment to this community and our Chamber is valued, seeing as most of their business attracts customers from across the United States and even internationally. They have been major sponsors of many of the Chamber fundraisers including the Legacy Sponsor for the last 3 years at the All Sports Spectacular. Other community events they are involved in are the Oh These Irish Hills ‘Row, Row, Row your cardboard boat,’ driving a car for the ‘Distinguished Young Women’ in the Christmas Parade, The Great American Crab Races at The Beach Bar, they even sponsored a little league softball team called the ‘Cootie Killers.’

Their vision of the Old Irish Mill, the former Ford Motor Co. plant in Brooklyn, is inspiring to see what this team has to bring to our community.

Because working with them IS contagious… please join me in congratulating TransPharm Preclinical Solutions, this year’s Business of the Year.


New C. difficile Offerings

Over the past several quarters, the TransPharm team has been busy performing numerous C. difficile studies and looking for ways to best serve our clients’ needs. As a result, we’ve added two new offerings to complement our robust model of C. difficile infection. These new features are Toxin A/B detection and recurrence studies.

The commercially available R-Biopharm RIDASCREEN® kit can be used to detect the presence of C. difficile Toxin A/B in stool samples. This is a great data set for our clients to complement the clinical scoring and weight loss observations.

We have also validated a longer version of our current C. difficile infection model to capture the recurrence event seen in the clinical setting. With mice receiving a C. difficile challenge on Day 0 and vancomycin QD from Days 0-4, we see recurrence on Day 8 as indicated by mortality and significant weight loss.

We feel these two new, clinically-relevant features will be advantageous to our clients who currently work in the C. difficile therapy development field. Please contact us for more information.

Dr. Santiago R. Lopez
Director of Research


As always, please feel free to contact us:
Through our website, www.transpharmsite.com
Our toll free INFECT line, 1-888-88-INFECT
Or dial me direct, 1-517-536-8210
Check us out on Facebook


 

Fall 2012

Posted by on 12:41 pm in Newsletters | 0 comments

A Note from the President

It is hard to believe that another year has come and gone, but here we are again. Getting bundled up and trying to stay warm is never easy, but it is hard to beat the beauty of Michigan in the fall season. The photograph below was taken in early October just outside the TransPharm facility. We are extremely lucky to be surrounded by 15 acres of trees and a pond, and our Northern property line border is on Stoney Lake Creek. Visiting clients are always pleasantly surprised by our location and the country feel of our facility. One client, in particular, was taken aback by a flock of wild turkeys outside our lab window. I was told he doesn’t get to see that in France! It’s also not uncommon to see the occasional fox or deer strutting across the grounds.

We truly do have a unique setting and would like to use this opportunity to invite you to come out and visit. I can’t guarantee that the wildlife will cooperate and offer you a glimpse, but I can promise that you will be impressed with our AAALAC accredited facility – inside and out.

Daniel Ross
President and CEO


17


The Next Level

During the holiday season, our TransPharm team has been busy brainstorming and researching the possibilities of taking our services to the next level…the next Biosafety Level that is. We’ve met with consultants and engineers concerning the best approach to upgrade our current, state-of-the-art facilities to a BSL 3 laboratory. This will provide our clients with even more infection models with which to screen their antimicrobials. Client inquiries into level 3 models have allowed us to formulate a list of top-priority model validations which include: tuberculosis, anthrax, brucellosis and rickettsial diseases. Of course, this would only be the beginning of potential models we could offer to our clients. If you have a request for early validation of a specific model, please don’t hesitate to contact us! Have a wonderful holiday season and we look forward to working with you in 2013.

Dr. Santiago R. Lopez
Director of Research


Holiday Office Hours

This is a reminder that the TransPharm offices and vivarium will be closed starting on December 21st and will reopen on January 2nd. The last day for mouse deliveries is December 17th, with studies ending on the 20th. Studies for early January should be booked before December 21st.

We will be checking email periodically. This is the best way to reach us during our break. Have a great holiday season and a wonderful new year.


As always, please feel free to contact us:
Through our website, www.transpharmsite.com
Our toll free INFECT line, 1-888-88-INFECT
Or dial me direct, 1-517-536-8210
Check us out on Facebook


 

Summer 2012

Posted by on 12:46 pm in Newsletters | 0 comments

A Note from the President

I’m proud to start out this newsletter by announcing that as of July 20th, TransPharm Preclinical Solutions has once again received a recommendation for accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International.

AAALAC accreditation is evaluated every three years. Programs constantly change, as do the regulations for the use of animals in research. AAALAC’s mission is to ensure that all of these changes are enforced and that the Program Description for our facility is accurate, complete, and in adherence. The continued success of our program is directly related to those individuals on our Institutional Animal Care and Use Committee (IACUC). I would like to personally thank the following individuals:

  • Libby Ziemke, IACUC administrator
  • Marci Peek, Chair
  • Dr. Megan Nowland, Attending Veterinarian and Alternate Chair
  • Joanne Zammit, Scientist
  • Dr. Santiago Lopez, Scientist
  • Dan Wymer, Non-Scientist
  • Dr. Jim Mobley, Alternate scientist

Adhering to these global standards is what led to our success three years ago, and this continued recommendation for accreditation bodes well for our continued success. To learn more about AAALAC International please visit www.aaalac.org.

Towards our commitment to high-quality research, four individuals here at TransPharm have recently received certification through the American Association of Laboratory Animal Science (AALAS). AALAS offers nationwide board exams after certain criteria are met. I would like to congratulate:

  • Heidi Richardson, ALAT level
  • Marci Peek, LAT level
  • Libby Ziemke, LATG level
  • Lisa Lazaroff, LATG level

To learn more about AALAS please visit www.aalas.org.

Daniel Ross
President and CEO


Clostridium difficile murine model

In an effort to provide our clients with the most robust and effective murine models of infection, TransPharm has adopted a new bacterial spore preparation for our C. difficile-associated disease model. This improved protocol has been thoroughly validated and rigorously compared to our previous procedure. It has surpassed TransPharm’s high standard of scientific excellence (Figures 1-3), much to the satisfaction of our valued clients with whom we’ve had the pleasure of collaborating.

CDAD-MortalityCDAD-Body WeightsCDAD-Fecal

So, if your group is in the market for a murine model of C. difficile-associated disease (or any other infectious disease model), there’s no better time to talk with us! Don’t forget – PK studies are also available here at TransPharm.

Dr. Santiago R. Lopez
Director of Research


ICAAC 2012

TransPharm will attend the 2012 ICAAC conference in San Francisco taking place September 9th – 12th. There have been many positive changes within TransPharm since the 2011 ICAAC in Chicago, including new animal models, management, and additions to our scientific team. Our new Director of Research, Dr. Santiago Lopez, will be joining us in San Francisco. Please stop by booth #1014 and welcome him to his first ICAAC.


As always, please feel free to contact us:
Through our UPDATED website, www.transpharmsite.com
Our toll free INFECT line, 1-888-88-INFECT
Or dial me direct, 1-517-536-8210
Check us out on Facebook


 

Spring 2012

Posted by on 12:07 pm in Newsletters | 0 comments

A Note from the President

TransPharm has given me some wonderful opportunities over the last 4 years. Locally, we volunteer for Junior Achievement, Big Brothers/Big Sisters, and donate to numerous charities that I wouldn’t have been able to in the past.

At the state level, we were recognized as one of the Top 50 Companies to Watch in Michigan in 2011. I was invited to a business round table discussion and met with Jennifer Granholm, Michigan’s outgoing Governor. I was also invited to Governor Rick Snyder’s residence in Lansing for the Moores River Drive Breakfast. Both events brought together many of the state’s business leaders and gave us a chance to meet with some of our state representatives to hear some of the new initiatives that are in the works for small business owners.

At the national level, TransPharm has traveled to both the East and West Coasts and many cities in between to attend the annual ICAAC conference. This year’s event is being held in San Francisco, California. Please stop by booth 1014 and say hello.

I feel extremely lucky to have traveled to London, England to attend the European Congress of Clinical Microbiology and Infectious Diseases. The conference boasted attendance from 106 different countries. It was my first trip to Europe and I can’t overstate how wonderful it was. Ironically, I met a family in our hotel that lives about 25 miles from me in Michigan. It just goes to show how small this world is these days. I’m already looking forward to attending the conference next year in Berlin, Germany.

Daniel Ross
President and CEO


London Tower Bridge visit during the ECCMID conference

London Tower Bridge visit during the ECCMID conference


TransPharm’s Development Incubator

To update you on our current model development here at TransPharm, I’d like to announce that our first viral sepsis model, Herpes Simplex Virus 1, is just about completed! Once the finishing touches are added within the next few days we’ll be ready to roll this out to all our interested clients (Figure 1). Also while the viral models are emerging from our development incubator, we’ve also established a neonatal rat sepsis model using Staphylococcus epidermidis (Figure 2). This model mimics the clinical manifestation sometimes seen in low birth weight human infections.

Figure 1 - HSV-1Figure 2 - S epidermidis

In recent months, a new, advantageous partnership has emerged between TransPharm and HuMurine Technologies (www.humurine.com). Using their proprietary Hu-M™ CIEA NOG mouse® model as a background, HuMurine has developed a commercialized humanized mouse, named the Hu-M™ ID Model, to study infectious disease. With their novel humanized mouse model and TransPharm’s preclinical testing experience, this joint venture has the potential to greatly benefit institutions that desire to test compound efficacy in a preclinical, human immunological environment. We are looking to develop a hu-mouse model for all current TransPharm pathogens, as well as new ones such as Malaria and Dengue. Stay tuned for updates on this exiting, new partnership!

Dr. Santiago R. Lopez
Director of Research


Dan Hits the Airwaves!

Dan Ross, President & CEO of TransPharm, was recently interviewed by the Michigan Business Network. Click the link below to listen to the podcast.

http://www.michiganbusinessnetwork.com/radio/2012/03/09/Business_Beat_S2_Daniel_Ross


As always, please feel free to contact us:
Through our UPDATED website, www.transpharmsite.com
Our toll free INFECT line, 1-888-88-INFECT
Or dial me direct, 1-517-536-8210
Check us out on Facebook